Real-world experience of dacomitinib in EGFR mutated advanced NSCLC: A single center experience from India.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.e21043
Abstract: e21043 Background: Dacomitinib is an irreversible tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) approved in advanced non-small cell lung cancer (NSCLC) with mutated EGFR. Literature on real world experience of dacomitinib is lacking,… read more here.
Keywords: response; dacomitinib; oncology; egfr ... See more keywords